(Press-News.org) ORLANDO, Fla. — Scientists are continuing their work on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial — known more commonly as the BATTLE trial — and presented updated results at the AACR 102nd Annual Meeting 2011, held here April 2-6.
John Heymach, M.D., Ph.D., associate professor of thoracic, head and neck medical oncology at The University of Texas MD Anderson Cancer Center, said this update details the "discovery phase" of the ongoing program.
"Last year, we presented results on pre-specified markers to determine how effective they would be at predicting response to EGFR inhibition. This year we worked in the other direction to try to discover and test novel gene markers that hadn't been pre-specified," said Heymach.
Researchers performed gene expression profiling and core needle biopsies on 101 patients in the BATTLE trial. They found that the presence of an EMT (epithelial-to-mesenchymal signature) and the presence of a novel five gene signature including LCN2 were predictive of response to erlotinib, including patients with wild-type EGFR, as measured by disease control rate and progression-free survival.
Heymach said thus far new markers were identified retrospectively in the BATTLE protocol. The upcoming BATTLE 2 protocol will test the predictive value of these gene signatures prospectively.
"The hope is that we'll be able to predict who will respond to EGFR inhibition with erlotinib, particularly among patients who do not have an EGFR mutation. We currently don't have any predictive markers for this group of patients. We also think a similar approach can be applied to other drugs," he said.
The first results of BATTLE, which were presented at the AACR 101st Annual Meeting 2010, are published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting at this year's Annual Meeting on Sunday, April 3.
The updated "discovery phase" results of the BATTLE trial will be presented during a press conference on Saturday, April 2 at 10:00 a.m. ET in room W313 of the Orange County Convention Center. Reporters who cannot attend in person can participate by using the following information:
U.S. & Canada: (888) 647-7462
International: (201) 604-0169
Access Code: 244078
###
Press registration for the AACR 102nd Annual Meeting 2011 is free to qualified journalists and public information officers: http://www.aacr.org/PressRegistration
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.
BATTLE researchers identify new biomarkers for EGFR inhibition
2011-04-03
ELSE PRESS RELEASES FROM THIS DATE:
Ringling College of Art and Design Annual Fundraiser Receives Major Contribution from Park West Gallery
2011-04-03
Ringling College of Art and Design in Sarasota, FL held its 14th annual scholarship fundraiser event, "An Evening at the Avant-Garde: Once Upon a Time," on Saturday, March 26, 2011. As a major sponsor of this year's event, Park West Gallery, now in its 42nd year as a leading fine art gallery, will help "make dreams come true" for Ringling students through its generous contribution to the school.
Park West Gallery is fulfilling its mission to promote art enrichment by providing Ringling with artwork for their Avant-Garde fundraiser. An eclectic mix of works by renowned ...
Sainsbury's Travel Money Launches Online Service
2011-04-03
Sainsbury's Travel Money today launches an online service that will allow customers to 'click and collect' their holiday money. The 0% commission on foreign currency, which offers competitive exchange rates, will give customers the choice of having their money delivered to home or collecting it from one of the 117 Sainsbury's Travel Money bureaux across the UK.
Sainsbury's shoppers who use the online Travel Money service will also benefit from an introductory offer of 1,000 Nectar points for every GBP500 of foreign currency they purchase. Furthermore, customers who choose ...
Get Help if Mounting Bills are Making it Difficult to Keep Up
2011-04-03
The IVA Advisory Centre has encouraged struggling consumers to take advantage of the wide range of help available if they feel mounting bills are affecting their ability to keep up with their other essential costs.
The comments come in response to a spate of price rises for consumers in recent months. Towards the end of last year, many saw their energy bills increase sharply - with further increases anticipated for this year by some analysts - and at the end of February, water industry regulator Ofwat announced that water bills would increase by an average of 4.6% from ...
Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity
2011-04-03
ORLANDO, Fla. — The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
The research, presented by Johanna Bendell, M.D., tests a combination of GDC-0973, which inhibits MEK1/2 and GDC-0941, which inhibits PI3K. Bendell, director of Gastrointestinal Oncology Research and associate director of the drug development unit at the Sarah Cannon Research Institute in Nashville, said the RAS/RAF/MEK and ...
LateRooms.com - Tennis Stars to Compete at Mutua Madrid Open
2011-04-03
Many of the world's top tennis players will head to Spain for the Mutua Madrid Open, which begins on Friday April 29th.
The ATP World Tour Masters 1000 event is due to run until Sunday May 8th at the Spanish capital's new Caja Magica stadium, also known as the Magic Box.
As the world's highest ranking tennis competition below the Grand Slams, the Masters Series is known for exciting events in which the sport's finest players can battle to become world number one.
The Mutua Madrid Open has been going as a men's tournament since 1990, but received a major overhaul ...
Chronic stress of cancer causes accelerated telomere shortening
2011-04-03
ORLANDO, Fla. — Results of a study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6, lend credence to the idea that improving quality of life affects stress-related biological markers and possibly the health of people with cancer.
Researchers know that telomeres shorten and deteriorate with aging, but they are learning that stress also affects telomere length.
"We are trying to understand the interconnections between the mind and the body; that is, how does the diagnosis and treatment of cancer impact patients not only psychologically, but also physiologically ...
Target for lung cancer chemoprevention identified
2011-04-03
ORLANDO, Fla. — Scientists have identified a biomarker for measuring the success of lung cancer chemoprevention, an emerging frontier in the fight against this disease that has long been stymied by a lack of measureable outcomes. These study results were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
Paul Bunn, M.D., executive director of the International Association for the Study of Lung Cancer and the James Dudley endowed professor of lung cancer research at the University of Colorado Cancer Center at the University of Colorado School of Medicine, ...
LateRooms.com - Organist Donald MacKenzie to Play in Pembrokeshire
2011-04-03
Donald MacKenzie, an organist who specialises in accompanying silent films, is due to perform at the Torch Theatre next month.
The Ayrshire-born musician is the house organist at the famous Odeon Cinema in London's Leicester Square, where he has been playing for various events since 1992.
Mackenzie has broadcast from the Odeon on several BBC radio stations, as well as playing for the Queen at numerous royal film performances.
His show at the Pembrokeshire venue will take place at 19:30 BST on Tuesday April 26th, when members of the audience are set to enjoy his ...
Genetic variation linked to longer telomeres and lower risk of bladder cancer
2011-04-03
ORLANDO, Fla. — Using new genetic information, scientists have linked a commonly found human genetic variant with both longer telomeres and reduced risk of bladder cancer, according to findings presented at the AACR 102nd Annual Meeting 2011, held April 2-6, and simultaneously published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Jian Gu, Ph.D., assistant professor of epidemiology at The University of Texas MD Anderson Cancer Center, said the single-nucleotide polymorphism (SNP) rs398652 on 14q21 was linked to both longer ...
DNA of 50 breast cancer patients decoded
2011-04-03
In the single largest cancer genomics investigation reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched DNA of the same patients' healthy cells. This comparison allowed researchers to find mutations that only occurred in the cancer cells.
They uncovered incredible complexity in the cancer genomes, but also got a glimpse of new routes toward personalized medicine. The work was presented at the American Association for Cancer Research 102nd Annual Meeting 2011.
In all, the tumors had more ...